We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Advances in the treatment of malignant gliomas.
- Authors
Khasraw, Mustafa; Lassman, Andrew B
- Abstract
Local control with surgery, radiation, and temozolomide chemotherapy remain the pillars of treatment for high-grade gliomas. Novel therapeutic strategies, including a variety of antiangiogenic agents, are under investigation. One of these agents, bevacizumab, was recently given accelerated approval by the US Food and Drug Administration as a single agent for recurrent glioblastoma. Recent trial results are generating important clinical questions regarding which patients to treat and when, and how best to monitor response. Encouraging results of recent studies are driving willingness to undertake aggressive treatment and to improve outcomes in this population. In this era, better understanding of biology, molecular aspects of cancer, and clinical trial methodology are crucial for clinicians. This review focuses on recent advances in the treatment malignant gliomas, especially antiangiogenic therapy.
- Publication
Current oncology reports, 2010, Vol 12, Issue 1, p26
- ISSN
1534-6269
- Publication type
Journal Article
- DOI
10.1007/s11912-009-0077-4